Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.
Risk factors for readmission among 132,400 #SLE hospitalizatiions included
Links:
You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.
Read ArticleDr. Jack Cush reviews the news and journal reports and takes viewer questions this week.
Read Article
Links:
Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic.
Downward Effects! Real world data from 22,934 UK #RA pts
Links:
The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.
The cohort included 8,120 AID patients from a national tertiary referral
Read Article
Links:
Links:
Links:
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.
Diagnostic delay in axial spondyloarthritis? Systematic review
Links:
Links:
Dr. John Cush @RheumNow( View Tweet )
Drs. Jack Cush and Artie Kavanaugh review the highlights of the RWCS (Rheumatology Winter Clinical Symposium) from Maui.
Dr. John Cush @RheumNow( View Tweet )
Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read Article
Analysis of two large cohorts of systemic sclerosis (SSc) patients shows a signfiicant minority of patients to have autoantibodies typical of rheumatoid erosive arthrits, but their presence in SSc patients was associated with unique manifestations of SSc.
Overall 448 SSC patiens were
Read Article
Genentech announced March 4th that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults SSc-ILD.
Read ArticleThere's good news and bad news in rheumatology fellowship matching for 2022. There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine.
Dr. Jack Cush reviews the latest news, journal reports, regulatory
Will the results of two recent large scleroderma lung studies finally inform us on how to manage interstitial lung disease in systemic sclerosis?
Read Post
